Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 17-18, 2024. The presentation schedule is su...
Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 PR Newswire SAN JOSE, Calif. , Jan. 10, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology co...
Anixa Biosciences Inc. (ANIX) is expected to report $-0.09 for Q4 2023 Eaco Corp. (EACO) is expected to report for Q2 2024 Rite Aid Corporation. (RADCQ) is expected to report $-1.45 for Q3 2024 KB Home (KBH) is expected to report $1.67 for Q4 2023 Dogness (International) Corporati...
Anixa Biosciences Inc. (ANIX) is expected to report $-0.09 for Q4 2023
Anixa Biosciences to Present at Biotech Showcase 2024 PR Newswire SAN JOSE, Calif. , Dec. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and...
2023-12-11 12:26:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example. Leading up to U.S. FDA rulings, the st...
2023-12-08 18:24:17 ET Summary Anixa Biosciences is a biotech specializing in immunotherapy treatments for breast and ovarian cancers. They are developing a vaccine for α-lactalbumin in triple-negative breast cancer and AMHR2 in ovarian cancer. ANIX is also involved in ...
2023-12-07 06:50:16 ET More on Anixa Biosciences Seeking Alpha’s Quant Rating on Anixa Biosciences Historical earnings data for Anixa Biosciences Financial information for Anixa Bioscience 8 For further details see: Anixa Bio falls after Phase 1 da...
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine PR Newswire – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T...
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine PR Newswire – Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – C...
News, Short Squeeze, Breakout and More Instantly...
Anixa Biosciences Inc. Company Name:
ANIX Stock Symbol:
NASDAQ Market:
Anixa Biosciences Inc. Website:
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology PR Newswire SAN JOSE, Calif. , July 17, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment an...
Anixa Biosciences Announces $5 Million Share Repurchase Program PR Newswire SAN JOSE, Calif. , July 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of ...
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial PR Newswire This patient is expected to be the final patient in the second dosage cohort of the trial SAN JOSE, Calif. , June 24, 2024 /PRNewswire/ -- Anixa Biosciences, I...